The Global Lutetium-177 (Lu-177) Market was valued at USD 1.85 Billion in 2024 and is projected to reach USD 6.38 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 16.9% during the forecast period (2025–2032). This growth is being driven by rising cancer prevalence with over 19.3 million new cases globally in 2023, expanding regulatory approvals for Lu-177 therapies like Lutathera® and Pluvicto™, and the accelerating adoption of targeted radionuclide therapies across neuroendocrine tumors and prostate cancer treatments.

As the nuclear medicine industry transforms toward precision oncology and theranostic solutions, the spotlight is on the key isotope producers who are driving innovation, scalable production, and accessible treatments. In this blog, we profile the Top 10 Companies in the Lutetium-177 (Lu-177) Industry—a mix of radiopharmaceutical developers, reactor operators, and production innovators shaping the future of global cancer care.

---

🔟 1. Cardinal Health Nuclear Pharma

Headquarters: Dublin, Ohio, USA
Key Offering: Lu-177 distribution, radiopharmaceutical compounding, theranostic logistics

Cardinal Health plays a crucial role in the Lu-177 supply chain by providing distribution and nuclear pharmacy services to hospitals and clinics across North America. Their expertise in handling short half-life isotopes ensures timely delivery for clinical use, supporting therapies like PSMA-targeted treatments. Recently, they partnered with ITM to enter the Lu-177 space, enhancing access for oncologists treating advanced cancers.

Innovation Initiatives:

• Strategic partnerships for Lu-177 supply expansion
• Advanced cold chain logistics for isotope delivery
• Integration into hospital theranostic programs

Download FREE Sample Report: Lutetium-177 (Lu-177) Market – View in Detailed Research Report

---

9️⃣ 2. Ion Beam Applications (IBA)

Headquarters: Louvain-la-Neuve, Belgium
Key Offering: Cyclotron-based Lu-177 production, radiopharma equipment

IBA is a leader in accelerator technology for medical isotopes, enabling efficient Lu-177 production through advanced cyclotron systems. Their equipment supports non-carrier-added Lu-177, critical for high-specific-activity therapies. Serving global nuclear medicine centers, IBA helps scale production to meet growing demand for precision cancer treatments.

Innovation Initiatives:

• Next-gen cyclotrons for higher Lu-177 yields
• Automated synthesis modules for clinical-grade isotopes
• Global installations supporting 120+ new facilities

---

8️⃣ 3. ITM Isotope Technologies

Headquarters: Munich, Germany
Key Offering: No-carrier-added Lu-177, radiopharmaceutical development

ITM specializes in isotope production and development of alpha- and beta-emitting radiopharma, with a strong focus on Lu-177 for oncology. Their platform technologies advance theranostics for prostate and neuroendocrine cancers. Collaborations with partners like Cardinal Health bolster their market position in therapeutic applications.

Innovation Initiatives:

• R&D pipeline for novel Lu-177 conjugates
• Capacity expansion via reactor partnerships
• Clinical trials for expanded cancer indications

---

7️⃣ 4. Curium Pharma

Headquarters: Paris, France
Key Offering: Lu-177 radiopharmaceuticals, diagnostic-therapeutic pairs

Curium Pharma strengthened its theranostics portfolio through the acquisition of Endocyte, positioning it as a key player in Lu-177 therapies. They supply isotopes and formulations for NETs and prostate cancer, with a focus on European markets. Their integrated approach supports seamless clinical workflows from diagnosis to treatment.

Innovation Initiatives:

• Acquisition-driven theranostics expansion
• Supply chain for EU regulatory compliance
• New formulation developments for better efficacy

Download FREE Sample Report: Lutetium-177 (Lu-177) Market – View in Detailed Research Report

---

6️⃣ 5. NTP Radioisotopes

Headquarters: Pretoria, South Africa
Key Offering: Reactor-produced Lu-177, bulk isotope supply

NTP Radioisotopes is a major supplier from its SAFARI-1 reactor, providing carrier-added and no-carrier-added Lu-177 to global markets. They support research and clinical needs, particularly in emerging regions. Their stable production ensures reliable supply amid growing theranostic demand.

Innovation Initiatives:

• Reactor optimization for Lu-177 purity
• Export capabilities to 80+ countries
• R&D for sustainable isotope processing

---

5️⃣ 6. ANSTO

Headquarters: Lucas Heights, Australia
Key Offering: High-purity Lu-177, medical radioisotope production

ANSTO, through its OPAL reactor, is a key producer of Lu-177, supplying therapeutic doses worldwide. They focus on high-quality isotopes for PSMA and DOTATATE therapies. As demand surges, ANSTO invests in capacity to serve Asia-Pacific growth.

Innovation Initiatives:

• OPAL reactor upgrades for increased output
• Partnerships with pharma for therapy development
• Quality assurance for global clinical trials

---

4️⃣ 7. SHINE Technologies

Headquarters: Janesville, Wisconsin, USA
Key Offering: Accelerator-produced Lu-177, reactor-free isotopes

SHINE Technologies disrupts Lu-177 production with non-reactor technology using particle accelerators, promising cost reductions of up to 60%. Their method addresses supply shortages, targeting commercialization in 2025. This innovation could transform accessibility for widespread cancer therapies.

Innovation Initiatives:

• Non-reactor production to cut costs
• Scalable facilities for domestic supply
• Focus on high-volume clinical-grade Lu-177

---

3️⃣ 8. Eckert & Ziegler Strahlen

Headquarters: Berlin, Germany
Key Offering: Carrier-added and n.c.a. Lu-177, full supply chain

Eckert & Ziegler holds a 22% market share with vertical integration from production to formulations. They recently expanded their Berlin facility to triple Lu-177 output by 2026, responding to PSMA therapy demand. Their experience spans two decades in isotopes.

Innovation Initiatives:

• Facility expansion to triple capacity
• Vertical integration for reliability
• R&D in synthetic Lu-177 pathways

---

2️⃣ 9. Advanced Accelerator Applications (Novartis)

Headquarters: Basel, Switzerland
Key Offering: Lutathera®, Pluvicto™ (Lu-177 therapies)

Advanced Accelerator Applications, a Novartis subsidiary, leads with 38% share through FDA-approved Pluvicto for prostate cancer. They invested $500M in 2023 to expand manufacturing. Their pipeline drives Lu-177 adoption in precision oncology.

Innovation Initiatives:

• $500M capacity expansion investment
• Broad clinical pipeline for new indications
• Theranostic platforms for NETs and PSMA

---

1️⃣ 10. Novartis AG

Headquarters: Basel, Switzerland
Key Offering: Comprehensive Lu-177 theranostics, global commercialization

Novartis dominates via its AAA subsidiary, commercializing blockbuster Lu-177 therapies like Lutathera and Pluvicto. They lead clinical adoption with response rates over 60% in trials. Global manufacturing expansions secure supply for rising cancer cases.

Innovation Initiatives:

• Leadership in FDA-approved Lu-177 drugs
• Strategic expansions for global access
• Combination therapy research synergies

Read Full Report: Lutetium-177 (Lu-177) Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Lutetium-177 is Theranostic and Scalable

The Lutetium-177 market is undergoing a dynamic shift. While current production constraints persist due to the isotope’s short half-life, the industry is investing billions in accelerator technologies, expanded reactors, and theranostic networks to meet surging oncology demand.

📈 Key Trends Shaping the Market:

• Rapid production capacity expansion globally with 120+ new facilities
• Regulatory push for expanded indications and combination therapies
• Theranostics integration with diagnostics like Ga-68 PET
• Strategic alliances between producers and pharma for supply security

Read Full Report: Lutetium-177 (Lu-177) Market – View in Detailed Research Report

The companies listed above are not only supplying critical Lu-177—they’re spearheading the precision therapy revolution in oncology.